Although the EpCAM and TROP2 proteins were discovered some time ago, only recently have they become the focus of research in various cancers. While there are increasing reports about the role of EpCAM or TROP2 in various cancers, only a few reports of EpCAM or TROP2 expression in NSCLC have been published [
2,
13]. In one recent study, EpCAM expression was investigated in NSCLC, but TROP2 was not involved [
2]. A study by Kobayashi
et al. has evaluated TROP2 expression in NSCLC [
13], and it was limited to small-sized AdC. Hence, the present study is the first comprehensive evaluation of the expression of EpCAM and TROP2 in pulmonary AdC and SCC, simultaneously.
In the present study, we observed different patterns of EpCAM and TROP2 expression between in normal bronchial epithelium and in NSCLC. In normal bronchial epithelium, both proteins showed only infrequent basolateral cytoplasmic membrane positivity. They were not stained in alveolar pneumocytes. As EpCAM is a cell-cell adhesion molecule in epithelial cells, its distribution along the cytoplasmic membrane is not unexpected. On the other hand, EpCAM and TROP2 were overexpressed in NSCLC and their staining along the cytoplasmic membrane was complete along the membrane. This finding corroborates a previous report that the expression of EpCAM increases in a stepwise manner from uninvolved bronchial mucosa, epithelial hyperplasia, to SCC [
2]. Cytoplasmic or nuclear expression was not seen in our study. Although Kobayashi
et al. advocated that TROP2 is also expressed in cytoplasm in NSCLC [
13] and we observed focal cytoplasmic staining, we think that this is non-specific staining regarding that cytoplasmic expression was only focally observed in the cases which show strong membranous TROP2 staining. Both EpCAM and TROP2 were more frequently expressed in SCC in the present study, being consistent with a previous study [
6]. But, the pattern of expression was not different to each other. Besides functioning as cell-cell adhesion molecule, EpCAM has been recently known to act as an oncogene, proving to trasduce cell proliferating signal through c-myc, cyclin D, and survivin. In another aspect, the loss of EpCAM has been advocated to promote tumor progression through weakening cell-cell adhesion. When EpCAM is overexpressed, some cancers such as stage I or II gastric cancer, stage II NSCLC, clear cell renal cell carcinoma, and stage II colon cancer show better survival while others such as node-positive breast cancer, epithelial ovarian cancer, gall bladder cancer, cholangiocarcinoma, ampullary pancreas cancer, squamous cell cancer of the esophagus, and squamous cell head and neck cancer do worse. This contradicting result may be determined by which function of cell-cell adhesion or oncogene of EpCAM predominates. Although the function of TROP2 is less defined than that of EpCAM, TROP2 has also been suggested as oncogene, promoting cancer cell proliferation and migration, and cell adhesion molecule [
5,
14]. Regarding NSCLC, Kobayashi
et al. reported that TROP2 overexpression in small pulmonary AdC was related with worse overall survival [
13]. However, in our study, TROP2 overexpression was related with better overall survival and disease free survival in AdC, although SCC showed same tendency but no statistical significance. To our best knowledge, there has not been a study, in which TROP2 overexpression in cancer was associated with better survival than those which do not. This discordance between our study and previous one may be partially explained by that Kobayashi
et al. included only AdC which are < 2 cm in size, while we included larger tumors of varying degree of differentiation. In our study, stage II or III AdC with TROP2 overexpression showed better overall survival and disease-free survival while in stage I AdC, TROP2 overexpression did not affect overall survival or disease-free survival. Furthermore, poorly differentiated AdCs expressed TROP2 more frequently. These data imply that poorly differentiated AdCs may show better survival when they express TROP2. Whether TROP2 serves as an adhesion molecule or not has not been fully defined. Some advocated its role as adhesion molecule [
15], but early study could not prove it [
16]. Recently, it has been discovered that TROP2 binds with Claudin 1 and 7 which are important components of tight junctions, taking part in cell-cell adhesion [
17]. Hence, we hypothesized that the biologic role of TROP2 can be different in early and advanced pulmonary AdC. In higher stage pulmonary AdC, the role of TROP2 as an adhesion molecule may be greater than as an oncogene. TROP2 overexpression may strengthen bonds between tumor cells, preventing their shedding and progression. Like EpCAM showed variable results in variable cancers, TROP2 may play different roles in different cancers.